(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Michael Jordan donates $10M to North Carolina medical center in honor of his mother- Instructions to Pick the Best Album Rates for Your Investment funds
- Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
- 'Stranger Things' Season 5: What's going on with Will Byers? That shocking Volume 1 plot twist, explained.
- Vote in favor of the wide open action that revives your brain and soul!
- JFK's granddaughter reveals terminal cancer diagnosis, criticizes cousin RFK Jr.
- 5 Pizza Fixings That Characterize Your Character
- Figure out how to Put resources into Lab Precious stones: A Novice's Aide
- The Way to Monetary Health: Individual budget Change
